Tag - Interface Biologics

Feature

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Closely-held Interface Biologics is selling its Endexo surface modification business and shifting its focus to its Epidel drug delivery technology, initially for ophthalmic indications.

September 3, 2019

Feature

Interface Biologics to focus future growth in biotech with local drug delivery platform

Closely-held Interface Biologics, best known for improving the safety and efficacy of medical devices through its Endexo surface modification technology, is pegging its future growth on biotech, with an initial focus on...

February 5, 2019

Executive Moves

Kelley Dealhoy joins Interface Biologics as VP of business development

Closely-held Interface Biologics (IBI) appointed Kelley Dealhoy to the position of VP business development.

December 4, 2018

Tag - Interface Biologics

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Interface Biologics to focus future growth in biotech with local drug delivery platform

Kelley Dealhoy joins Interface Biologics as VP of business development

General

More